vs
Side-by-side financial comparison of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) and American Express (AXP). Click either name above to swap in a different company.
ASCENTAGE PHARMA GROUP INTERNATIONAL is the larger business by last-quarter revenue ($32.6M vs $18.9M, roughly 1.7× American Express).
Ascentage Pharma Group International is a global clinical-stage biotechnology company specializing in developing novel targeted therapies for cancers, chronic viral infections, and age-related diseases. It focuses on small molecule drugs targeting apoptosis pathways and other key oncogenic mechanisms, with operations spanning China, the U.S., and other global markets, serving patients with unmet medical needs worldwide.
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
AAPG vs AXP — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $32.6M | $18.9M |
| Net Profit | $11.4M | $3.0M |
| Gross Margin | 90.7% | — |
| Operating Margin | — | — |
| Net Margin | — | 15.7% |
| Revenue YoY | — | 11.4% |
| Net Profit YoY | — | 15.0% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $18.9M | ||
| Q4 25 | — | $10.9B | ||
| Q3 25 | — | $10.4B | ||
| Q2 25 | $32.6M | $10.3B | ||
| Q1 25 | — | $9.6B | ||
| Q4 24 | — | $10.0B | ||
| Q3 24 | — | $9.7B | ||
| Q2 24 | — | $9.8B |
| Q1 26 | — | $3.0M | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | $11.4M | $2.9B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $3.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 90.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 28.2% | ||
| Q3 25 | — | 36.7% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 34.6% | ||
| Q4 24 | — | 27.7% | ||
| Q3 24 | — | 33.0% | ||
| Q2 24 | — | 38.6% |
| Q1 26 | — | 15.7% | ||
| Q4 25 | — | 22.5% | ||
| Q3 25 | — | 27.9% | ||
| Q2 25 | — | 28.0% | ||
| Q1 25 | — | 26.8% | ||
| Q4 24 | — | 21.8% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 30.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | $3.52 | ||
| Q3 25 | — | $4.14 | ||
| Q2 25 | — | $4.08 | ||
| Q1 25 | — | $3.64 | ||
| Q4 24 | — | $3.04 | ||
| Q3 24 | — | $3.49 | ||
| Q2 24 | — | $4.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | $60.4M |
| Stockholders' EquityBook value | — | $34.0M |
| Total Assets | — | $308.9M |
| Debt / EquityLower = less leverage | — | 1.78× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $742.0M | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $197.0M | ||
| Q1 25 | — | $261.0M | ||
| Q4 24 | — | $221.0M | ||
| Q3 24 | — | $120.0M | ||
| Q2 24 | — | $188.0M |
| Q1 26 | — | $60.4M | ||
| Q4 25 | — | $56.4B | ||
| Q3 25 | — | $57.8B | ||
| Q2 25 | — | $58.2B | ||
| Q1 25 | — | $51.2B | ||
| Q4 24 | — | $49.7B | ||
| Q3 24 | — | $53.5B | ||
| Q2 24 | — | $51.5B |
| Q1 26 | — | $34.0M | ||
| Q4 25 | — | $33.5B | ||
| Q3 25 | — | $32.4B | ||
| Q2 25 | — | $32.3B | ||
| Q1 25 | — | $31.2B | ||
| Q4 24 | — | $30.3B | ||
| Q3 24 | — | $29.7B | ||
| Q2 24 | — | $29.5B |
| Q1 26 | — | $308.9M | ||
| Q4 25 | — | $300.1B | ||
| Q3 25 | — | $297.6B | ||
| Q2 25 | — | $295.6B | ||
| Q1 25 | — | $282.2B | ||
| Q4 24 | — | $271.5B | ||
| Q3 24 | — | $271.0B | ||
| Q2 24 | — | $272.2B |
| Q1 26 | — | 1.78× | ||
| Q4 25 | — | 1.68× | ||
| Q3 25 | — | 1.78× | ||
| Q2 25 | — | 1.80× | ||
| Q1 25 | — | 1.64× | ||
| Q4 24 | — | 1.64× | ||
| Q3 24 | — | 1.80× | ||
| Q2 24 | — | 1.74× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAPG
| Products | $29.7M | 91% |
| Others | $2.9M | 9% |
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
